BAY-784 is a novel, potent, orally bioavailable, and selective gonadotropin releasing hormone receptor (GnRH-R) antagonist with IC50s of 21 and 24 nM for human and rat GnRH-R, respectively. In a first-in-human study in postmenopausal women, once daily treatment with BAY 1214784 effectively lowered plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability.

纯度：≥98%

CAS：1631164-24-3